Immunological therapy in urological malignancy: Novel combination strategies

Authors


David S Finley md, Institute of Urologic Oncology, David Geffen School of Medicine at UCLA, 924 Westwood Blvd, Suite 1050, Los Angeles, CA 90024, USA. Email: dfinley@mednet.ucla.edu

Abstract

At present, immunotherapy in urological malignancy is experiencing a renaissance, particularly with the emergence of a host of innovative cancer vaccines. Herein, we will review promising immunotherapeutic approaches and evaluate the data supporting their inclusion in novel combination strategies.

Ancillary